1. Scrip

The Eyes Have It For Shire With Lifitegrast Filing In Europe

 
• By Kevin Grogan

The drug, marketed across the Atlantic as Xiidra, has already made significant inroads in the US dry eye market which has been dominated by Allergan's Restasis

Market share
Shire is after a bigger slice of the dry eye market • Source: Shutterstock

Shire's bid to further boost its presence in the dry eye disease market has been boosted by the submission of lifitegrast in Europe.

The company says that the marketing authorization application for lifitegrast, submitted last week, has been validated by the UK as the reference member state involved in the decentralized procedure

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

More from Therapy Areas

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.